Abstract
For the last several years, the drug industry primarily has relied on drugs that target a single gene or enzyme in a pathway involved in disease progression with the idea that such a drug will have minimum side effects and maximal efficacy. Recent observations, however, indicate that a drug that targets multiple genes/enzymes involved in several pathways, thus exhibiting promiscuity, is often more efficacious with less side effects. Thus significant efforts are being made to use our understanding in pharmacogenomics and structural biology to design polypharmacological drugs that are able to act at multiple sites. Recent studies with pathogenic bacteria demonstrate that such bacteria produce water-soluble, low molecular weight redox proteins that appear to act as weapons against various invaders, internal or external, of human body that cause diseases such as cancers, malaria or AIDS. The potential of finding such promiscuous lipophilic bacterial proteins active against multiple diseases may lead in the future to an antibiotic-like industry targeted towards non-prokaryotic agents of human diseases.
Keywords: Azurin, Cancer, Malaria, AIDS, Bacterial pathogenicity, Single and multiple target drugs
Letters in Drug Design & Discovery
Title: Designing Promiscuous Drugs? Look at What Nature Made!
Volume: 4 Issue: 1
Author(s): Arsenio M. Fialho, Tapas K. Das Gupta and Ananda M. Chakrabarty
Affiliation:
Keywords: Azurin, Cancer, Malaria, AIDS, Bacterial pathogenicity, Single and multiple target drugs
Abstract: For the last several years, the drug industry primarily has relied on drugs that target a single gene or enzyme in a pathway involved in disease progression with the idea that such a drug will have minimum side effects and maximal efficacy. Recent observations, however, indicate that a drug that targets multiple genes/enzymes involved in several pathways, thus exhibiting promiscuity, is often more efficacious with less side effects. Thus significant efforts are being made to use our understanding in pharmacogenomics and structural biology to design polypharmacological drugs that are able to act at multiple sites. Recent studies with pathogenic bacteria demonstrate that such bacteria produce water-soluble, low molecular weight redox proteins that appear to act as weapons against various invaders, internal or external, of human body that cause diseases such as cancers, malaria or AIDS. The potential of finding such promiscuous lipophilic bacterial proteins active against multiple diseases may lead in the future to an antibiotic-like industry targeted towards non-prokaryotic agents of human diseases.
Export Options
About this article
Cite this article as:
Fialho M. Arsenio, Das Gupta K. Tapas and Chakrabarty M. Ananda, Designing Promiscuous Drugs? Look at What Nature Made!, Letters in Drug Design & Discovery 2007; 4 (1) . https://dx.doi.org/10.2174/157018007778992946
DOI https://dx.doi.org/10.2174/157018007778992946 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
High-dose Everolimus May Induce Pro-inflammatory/Fibrotic Transcriptomic
Changes in Bronchial Epithelial Cells from Cystic Fibrosis
Patients
Current Pharmacogenomics and Personalized Medicine Base-Modified Nucleosides as Chemotherapeutic Agents: Past and Future
Current Topics in Medicinal Chemistry Metabolic Imbalance of Homocysteine and Hydrogen Sulfide in Kidney Disease
Current Medicinal Chemistry The Interrelationship Between Disease and Ageing and the Implications for Longevity
Current Aging Science Is the Modulation of Autophagy the Future in the Treatment of Neurodegenerative Diseases?
Current Topics in Medicinal Chemistry Translational Multimodality Neuroimaging
Current Drug Targets GPER and ER: Estrogen Receptors with Distinct Biological Roles in Breast Cancer
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Recent Advances in the Development of Multi-Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry Recent Advances in Peroxisome Proliferator-Activated Receptor Science
Current Medicinal Chemistry Nucleic Acid Aptamers Against Protein Kinases
Current Medicinal Chemistry IDO+ DCs and Signalling Pathways
Current Cancer Drug Targets Patent Selections:
Recent Patents on Anti-Infective Drug Discovery Current Guidelines and Strategies in Management of Renal Vein Thrombosis
Current Pediatric Reviews Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis
Current Pharmaceutical Design Hypomethylation of Urokinase (uPA) Promoter in Breast and Prostate Cancer: Prognostic and Therapeutic Implications
Current Cancer Drug Targets Drug-Mediated Targeted Disruption of Multiple Protein Activities Through Functional Inhibition of the Hsp90 Chaperone Complex
Current Medicinal Chemistry Birt-hogg-Dubé Syndrome Incidentally Identified in a Potential Liver Donor
Current Medical Imaging Biological Evaluation of <sup>99m</sup>Tc-HYNIC-EDDA/tricine-(Ser)<sub>3</sub>-D4 Peptide for Tumor Targeting
Current Radiopharmaceuticals The Current WHO Classification of Tumours of the Central Nervous System: Histopathology and Additional Diagnostic Methods
Current Medical Imaging Therapeutic Targeting of NLRP3 Inflammasomes by Natural Products and Pharmaceuticals: A Novel Mechanistic Approach for Inflammatory Diseases
Current Medicinal Chemistry